News
GlobalData on MSN12h
ASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancerUS-based biotechnology company Imunon has reported positive results from its Phase II OVATION 2 trial of IMNN-001 for ovarian ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback